Telik Announces Clinical Hold on TELCYTA Trials PALO ALTO, Calif., June 04, 2007 -- Telik, Inc. announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the ...

All the Telik (NASDAQ:TELK) critics, including myself, got a little egg on their faces today when the drugmaker announced that the FDA had removed the partial hold it had put on the development of its ...

Palo Alto , CA, February 11, 2009 - Telik, Inc. (Nasdaq: TELK) announced today that it is implementing a reorganization to focus on its most advanced preclinical and clinical drug development programs ...

MabVax Therapeutics, Inc., a privately held cancer immunotherapy company and Telik, Inc. (Nasdaq: TELK), aclinical stage oncology drug development company have entered into a definitive merger ...

Shares in US drugmaker Telik fell through the floor after the company announced that its new cancer drug failed to meet primary goals in three late-stage trials. Shares in US drugmaker Telik fell ...

Cynthia M. Butitta is Telik's Chief Operating Officer and Chief Financial Officer. She joined the company in 1998 as Chief Financial Officer. Ms. Butitta has extensive financial and operational ...

SAN DIEGO, July 9, 2014 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held cancer immunotherapy company, and Telik, Inc. (Nasdaq: TELK), a publicly-traded clinical stage oncology drug ...

Telik, Inc. has announced that its library of diverse profiled compounds now exceeds 3.3 million. The expanded library significantly enhances Telik's patented drug discovery technology, Target Related ...

The faithful followers of Telik Inc.'s Telcyta got their waited-for reward in Phase II data from a combination trial with the drug against non-small-cell lung cancer, and shares increased enough to ...

BOSTON, April 17 (Reuters) - Biotechnology company Telik Inc. said on Tuesday its experimental cancer drug, Telcyta, staved off the disease and improved survival following chemotherapy in lung cancer ...

Telik of Palo Alto, which three years ago was widely hailed as one of the country’s most promising biotech stocks, lost nearly 71 percent of its market value Tuesday when studies showed the ...